• For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops.
• What makes CHD numbers particularly troubling is that so much of this is preventable.
• Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level.

Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means that many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.

For decades, cardiovascular risk assessment has centered on a checklist. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops, and the data increasingly shows the gaps this leaves behind. Coronary heart disease is the most common form of cardiovascular disease (“CVD”) and often develops without symptoms, with a heart attack frequently serving as the first indication of disease. For many patients, by the time a traditional risk factor shows up, the disease may already be well underway.

The scale of the problem is significant. In the United States, one in 20 adults over the age of 20 lives with CHD, and it is the second leading cause of hospitalization, adding approximately $13,000 in annual healthcare costs per patient. The human toll is even starker. Heart attacks occur approximately every 40 seconds in the U.S., with more than 800,000 events annually, and one in five occurring without warning. There is also a lesser-known subset of the disease that adds further complexity. An additional three to four million Americans are affected by ischemia with no obstructive coronary arteries (“INOCA”), a subset of CHD.

What makes these numbers particularly troubling is that so much of this is preventable. An estimated 80% of cardiovascular disease is preventable through early detection and proactive management, yet the tools used to identify who needs that early intervention are missing more cases than they catch. A risk calculator with an average sensitivity of 39% means that for every 100 people who will experience a CHD event, on average, 39 of them would be flagged. Many patients walk out of a routine checkup with a clean bill of health, even as the disease quietly progresses.

This is the gap that Cardio Diagnostics is focusing on addressing. Rather than relying solely on the conventional risk factor checklist, the company has developed clinical tests rooted in genetics, the DNA blueprint, and epigenetics, the field that examines how genes are expressed and regulated at the molecular level, often in response to lifestyle, environment and underlying disease processes long before signs and symptoms may appear.

The company’s flagship offering, Epi+Gen CHD, is a blood-based test that assesses a patient’s three-year risk of experiencing a coronary heart disease event, including a heart attack, by analyzing a targeted panel of three epigenetic and five genetic biomarkers. Because these biomarkers can reflect biological changes happening regardless of the shifts in traditional markers, the test is designed to identify risk in people who may otherwise be classified as lower risk using standard tools.

The company also offers PrecisionCHD, which is also a clinical blood test designed to aid in the diagnosis of CHD. This solution analyzes a targeted panel of six epigenetic and 10 genetic biomarkers that are closely associated with CHD. Using artificial intelligence, the test predicts CHD signal with high sensitivity, supporting management of stable ischemic heart disease.

These tests are not a wholesale replacement for existing cardiology practice but rather an attempt to fill a documented and substantial blind spot. Traditional risk factors remain clinically relevant and continue to play a role in patient evaluation. What molecular biomarker testing adds is a second lens, one that can pick up signals the first lens was never built to detect.

For a disease that often gives no warning before a heart attack occurs, any tool that shifts the odds toward earlier detection carries meaningful weight. With more than 800,000 CHD events annually, and one in five heart attacks occurring without warning, and with the majority of cardiovascular disease considered preventable when caught early, the cost of missed detection is measured not just in healthcare dollars but in lives.

Cardio Diagnostics is positioning its epigenetics-based testing as part of the answer to that gap, offering physicians and patients a way to see risk that conventional tools have consistently struggled to capture. As the data on traditional risk calculator performance continues to circulate among clinicians and researchers, the case for incorporating molecular diagnostics into routine cardiovascular testing may continue to build.

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

• APUS is aligning its treasury strategy with the shift from Bitcoin ownership to Bitcoin productivity via yield and digital credit markets
• MindWave is focused on institutional-grade custody, treasury optimization and compliant digital asset infrastructure
• The updates highlight MindWave’s broader mission: to enable institutions to transform Bitcoin from a passive reserve asset into productive, yield-generating capital

The digital asset industry is entering a new phase of development. While early blockchain adoption was largely driven by speculation and asset appreciation, today’s market is increasingly focused on building sustainable financial infrastructure capable of supporting long-term institutional participation. Companies that can facilitate this transition are beginning to occupy an increasingly important role within the evolving digital asset ecosystem.

MindWave Innovations Inc. (NYSE American: APUS) is positioning itself within a structural transformation in corporate Bitcoin strategy, as institutional players move from simply holding BTC on balance sheets to actively deploying it within yield-generating financial systems. This shift highlights a broader maturation of the digital asset ecosystem, where Bitcoin is increasingly treated not only as a store of value but also as programmable collateral capable of supporting new forms of credit creation and liquidity generation.

This shift is becoming evident as traditional financial institutions quietly adopt technologies and operational frameworks that first emerged within decentralized finance (“DeFi”). What began as experimental blockchain-based lending, staking, liquidity provisioning and treasury management systems has evolved into a broader blueprint for more efficient capital markets. As a result, the conversation is moving beyond simple digital asset ownership and toward how these assets can be productively deployed within transparent, yield-generating financial ecosystems.

The result is an industry-wide transition from speculative participation toward operational utility, where digital assets function not only as stores of value but as productive components of broader financial infrastructure.

Companies developing institutional-grade digital asset infrastructure are becoming increasingly important participants in the industry’s evolution. As organizations seek secure custody, transparent treasury management yield optimization and regulatory compliance, demand is growing for platforms capable of supporting digital assets as productive financial instruments rather than passive holdings.

MindWave’s recent strategic initiatives reflect many of these emerging priorities. The company has been advancing a platform designed to support institutional participation in digital asset treasury management through board-controlled custody frameworks, insured treasury wallets, audit-ready reporting, AI-powered treasury optimization tools and structures designed for corporate oversight. As the Bitcoin treasury landscape expands and digital credit markets continue to scale, MindWave appears positioned to participate in a broader evolution of corporate finance, one in which Bitcoin is increasingly utilized as productive capital rather than simply held as a reserve asset.

For more information, visit the company’s website at www.MindWaveDAO.com.

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

• Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions.
• The  milestone highlighted in Quantum BioPharma’s announcement is that patient enrollment in a key pilot study has reached its halfway mark.
• Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions.

Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection, rigorous data collection and ongoing regulatory oversight, all in pursuit of a single goal — generating reliable evidence that a new drug, device or diagnostic tool is both safe and effective. Without this structured process, promising laboratory discoveries would never make the leap to treatments that physicians can confidently prescribe and patients can trust. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, recently announced in its collaborative imaging study with Massachusetts General Hospital (“MGH”) that the study has reached the halfway point in patient enrollment and early imaging results could support development of its multiple sclerosis drug candidate: Lucid-MS.

Studies of this kind sit at the center of how medicine advances. Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions: Does the approach work as intended? Is it safe? And can it reliably detect or measure what researchers claim it can? Imaging studies, in particular, often serve a dual purpose. They can validate new diagnostic tools while also generating data that helps assess how well an experimental treatment is performing inside the body.

This is especially important in diseases such as multiple sclerosis, where progression and treatment response have traditionally been difficult to measure with precision. Standard imaging techniques can show overall lesion activity, but they often cannot directly distinguish between damaged myelin with intact underlying nerve fibers and more severe, irreversible nerve damage. A tool capable of making that distinction would give researchers a clearer picture of whether a therapy is genuinely protecting or repairing the nervous system, rather than simply masking symptoms.

That clarity matters not just for individual patients but for the broader drug-development pipeline. Regulatory agencies increasingly look for objective, quantifiable biomarkers that can demonstrate a drug’s biological effect, not just its impact on symptoms. Qualified biomarkers can reduce uncertainty in regulatory decision-making, support more efficient clinical trial design and help identify patient populations most likely to demonstrate treatment effects, potentially reducing study size and duration while providing earlier evidence of drug activity. For smaller biopharmaceutical companies developing novel mechanisms, having access to this kind of precise measurement tool can be a meaningful advantage in both clinical development and conversations with regulators and potential partners.

Quantum BioPharma’s MGH collaboration is built around a novel positron emission tomography (“PET”) imaging technique using the tracer [¹⁸F]3F4AP, developed by Dr. Pedro Brugarolas, an investigator in the radiology department at MGH and assistant professor at Harvard Medical School. The technique is designed to directly assess demyelinated neurons that still have intact axons, offering a more precise way to track demyelination, the process underlying MS, than has previously been available.

Highlighted in the announcement is that patient enrollment in the study has now reached its halfway mark. Reaching the midpoint of enrollment is a meaningful operational step in any clinical study, as it indicates the trial is progressing on schedule and moving closer to having a dataset large enough to draw more confident conclusions.

The second highlight concerns the imaging results themselves. According to the company, the first cohort of participants has been imaged using both advanced PET/MR and total-body PET platforms. Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions. If these early findings hold up as enrollment continues, the company believes the imaging approach could provide a more direct and quantitative way to measure myelin loss and repair over time.

“We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data,” said Dr. Andrzej Chruscinski, VP of scientific and clinical affairs at Quantum BioPharma. “PET imaging with [¹⁸F]3F4AP has the potential to fundamentally change how we assess demyelination, providing a direct window into axonal health and enabling us to more clearly demonstrate the impact of therapies such as Lucid-MS that aim to protect and restore the myelin sheath in MS.”

Brugarolas stated that being able to directly quantify demyelinated lesions with intact axons in living patients addresses an important gap in MS research. “If further validated, this imaging approach could provide a more direct and quantitative measure of myelin loss and repair, which may help improve the evaluation of disease mechanisms and therapeutic response in MS,” he said.

The company noted that this imaging platform could play a role in the continued development of Lucid-MS, its investigational compound designed to inhibit demyelination by targeting protein arginine deiminase 2 (“PAD2”), an enzyme implicated in myelin degradation. Lucid-MS previously completed phase 1 clinical trials with a favorable safety profile, and the company submitted an Investigational New Drug (“IND”) application for a phase 2 trial to the U.S. Food and Drug Administration in March 2026.

For a company such as Quantum BioPharma, this type of progress represents more than a procedural checkbox. Multiple sclerosis affects more than 2.8 million people worldwide, and while treatments exist to manage the immune response, no therapy has yet demonstrated the ability to reliably halt or reverse the underlying nerve damage that drives long-term disability. The combination of a novel imaging tool that can directly visualize that damage and a drug candidate designed to address it at the source puts Quantum BioPharma in a distinctive position. Reaching the halfway point in enrollment, with early imaging data already showing meaningful impact, suggests the science is holding up under real-world clinical conditions, and that the path toward a more complete picture of both the disease and the therapy’s potential is coming steadily into view.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• Safe Pro Group Inc. (NASDAQ: SPAI) has announced that it has delivered against a recent $742,000 U.S. Army order for the company’s Threat Analysis Kits.
• The delivered kits include Safe Pro’s edge compute AI powered Navigation Observation & Detection Engine (“NODE”), Black Widow drones from Red Cat Holdings, annual AI model and algorithm software upgrades and operational field analysis support.
• Safe Pro was awarded the subcontract and order from a Defense Prime Contractor on behalf of the Army which is seeking field-ready battlefield intelligence capability powered by advanced AI technology.

Safe Pro Group (NASDAQ: SPAI), a mission-driven tech company that develops AI-powered security and defense solutions, recently announced that it has rapidly delivered against a U.S. Army order for Threat Analysis Kits under an award valued at around $742,000 (https://ibn.fm/smCGt).

The Threat Analysis Kit includes Safe Pro’s edge compute AI powered Navigation Observation & Detection Engine (“NODE”) and Black Widow drones from Red Cat Holdings. It also features annual AI model and algorithm software upgrades and field support.

Safe Pro Group was recently awarded the subcontract from a Defense Prime Subcontractor and contracted to provide the U.S. Army with a turnkey, field-ready battlefield intelligence capability powered by its patented AI technology that processes the video and images captured by the Black Widow drones. It was also contracted to provide upgrades, training, and operational support.

Safe Pro anticipates that the training of U.S. Army personnel will take place before the end of June, and it will be providing support throughout the third quarter of 2026 and through upcoming planned exercises.

The NODE edge compute system, which is powered by Safe Pro’s Safe Pro Object Threat Detection (“SPOTD”) technology, uses AI and machine learning to identify small and easily missed threats like mines, cluster munitions, ambush drones, and unexploded ordnance (“UXO”). The platform is capable of identifying over 150 different threats across large-scale and high-risk environments.

It also operates on the edge without any need for connectivity and enables better battlefield situational awareness as it provides the rapid generation of things like vegetation height, terrain, slope, digital surface maps, and 3D models.

Safe Pro’s technology converts raw visual data into high-resolution and shareable maps and offers a scalable approach to battlefield awareness. The dataset contains more than 2.8 million drone images and has achieved over 50,368 confirmed detections across more than 35,000 acres of land in Ukraine.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that delivers AI-powered security and defense solutions to customers within industries like homeland security, law enforcement, defense, humanitarian, and commercial markets. At the center of Safe Pro’s mission is a patented computer vision software technology which rapidly detects small objects in drone imagery and video, to help enable safer and more efficient field operations for ground teams.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

• The 10 cities with the largest police departments in the United States have paid out $1.02 billion for settlements and court judgements in police misconduct cases, with most centered around the improper use of force
• Wrap Technologies is well-positioned to establish a commanding position in supplying non-lethal tools to law enforcement departments globally
• Over 140 police departments across the United States received BolaWrap products in 2019, along with police departments in 19 other countries
• The company has received over 1,700 requests for demos, training and quotes from U.S. police departments, as well as over 600 requests from international markets
• Wrap Technologies can currently manufacture up to 1,800 BolaWrap devices per month, with plans to expand production capacity to 3,600 per month
• BolaWrap leverages strong intellectual product, with five U.S. patents granted and a further eight U.S. patents pending; the company has also filed four trademarks and has patents pending in 34 additional countries
• The addressable market size for non-lethal weapons is forecast to grow in size to $11.85 billion by 2023 (versus $6.32 billion in 2016)
• The company successfully raised $12.4 million through a primary share equity placement in June 2020, with proceeds destined to scale engineering, fund product development and provide working capital

Wrap Technologies (NASDAQ: WRAP) is an innovator of modern policing solutions. The company’s BolaWrap(R) product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award-winning inventor Elwood Norris, the company’s chief technology officer, the small-but-powerful BolaWrap assists law enforcement in safely and effectively controlling encounters, especially those involving an individual experiencing a mental crisis.

Non-Lethal Weapons Market Potential

The BolaWrap Remote Restraint device is an innovative police solution, designed to provide law enforcement with a unique mobile and humane restraint option that does not inflict pain and enables subjects to be detained from a distance without the use of force.

In 2015, the 10 cities with the largest police departments in the United States paid out a cumulative $248.7 million in settlements and court judgements in police misconduct cases, marking a 48% increase from the $168.3 million in 2010 (https://ibn.fm/ydMmC). The majority of these cases have centered around the improper use of force by law enforcement when subjugating individuals, with 25% of all fatal shootings by law enforcement in the United States reportedly involving mentally ill individuals who are often incapable of comprehending officer commands (https://ibn.fm/5HV8F). Moreover, the use of alternate devices has failed to produce the desired outcomes, with the use of tasers by police resulting in over 1,080 fatalities since 2000 (https://ibn.fm/I7lfP).

This, in turn, has led to a greater demand for humane tools which are not reliant on pain compliance to subdue subjects. Since its IPO in December 2017, Wrap Technologies has enjoyed a spectacular rise in prominence. The company began field testing the BolaWrap product in July 2018, with the first international order received only a month later, in August 2018. By December 2018, the company had been uplisted to the Nasdaq Capital Market with over 1,000 shareholders – a significant increase from the 50 shareholders who had participated in the IPO just 12 months prior. Recently, the company has sought to increase its commerciality and product monetization, appointing Tom Smith, the founder of TASER International (now Axon, NASDAQ: AAXN), as its president in March 2019.

At present, over 140 police departments throughout the United States are actively carrying the BolaWrap, while over 1,700 police departments across the nation have reached out to the company to request BolaWrap demonstrations, training and quotes. BolaWrap has also been successfully marketed internationally and has been shipped to 19 countries thus far.

As of today, Wrap Technologies has built a network of 11 distributors across 45 states in the United States who are actively marketing the product to the over 900,000 active police officers in the country. In addition, the company now has a network of 15 international distributors based in 26 countries – with over 600 international requests received thus far for product demonstrations, training and quotes.

As a result and following the opening of its new 11,000-square-foot manufacturing facility in Tempe, Arizona, in October 2019, Wrap Technologies announced a 352% year-on-year increase in revenues for 3Q2019 – a testament to the growing popularity of its mobile restraint device.

The company expects its growth to continue as adoption rates of the BolaWrap product increase throughout the United States and globally. According to a study by Stratistics MRC, the addressable global market for non-lethal weapons accounted for $6.32 billion in 2016 and is set to rise to $11.85 billion by 2023.

Product Received to Positive Acclaim

• “An innovation that is changing the world of policing.” – Chief Luther Reynolds, Charleston Police Department
• “Anytime you can have a more humane response to someone in crisis, it’s not only good for the department, it’s good for society.”– Redditt Hudson, Regional Field Director of the NAACP (https://ibn.fm/VV3gw)
• “This is going to save lives.” – Chief Ed Hudak, Coral Gables Police Department
• “I see this as one of the great tools if you encounter someone with a mental health crisis.” – Chief Steven Casstevens, Buffalo Grove Police Department

Recently completed $12.4 million financing round

Wrap Technologies announced that it had successfully completed its capital raising round on June 4, 2020, raising $12.4 million through a primary share placement priced at $6.00/share. The net proceeds will be used to further scale engineering, fund product development and provide working capital to meet worldwide demand for BolaWrap products and accessories (https://ibn.fm/6g4HZ). The company also announced that its founder, Elwood Norris, had chosen to exercise 100,000 outstanding warrants to contribute $500,000 to the capital raising efforts. Following the financing round, Wrap Technologies reported over $30 million in cash on hand.

Management Team

Elwood G. “Woody” Norris, Founder and Chief Technology Officer
Elwood G. “Woody” Norris is an award-winning American inventor and serial entrepreneur and currently serves as chief technology officer for Wrap Technologies Inc. Norris founded and served as a director and president of Parametric Sound Corporation (now Turtle Beach Corporation (NASDAQ:HEAR)) and also served as chief scientist at Turtle Beach. Norris previously founded LRAD Corporation (NASDAQ: LRAD) and, prior to retiring in 2010, was chairman of LRAD Corporation’s board of directors, serving as a technical advisor and product spokesperson. Norris has authored more than 80 U.S. patents, primarily in the fields of electrical and acoustical engineering, and has been a frequent speaker on innovation to corporations and government organizations. He is the inventor of Wrap Technologies’ patented and patent pending BolaWrap(R) technology.

Scot Cohen, Executive Chairman
Scot Cohen has more than 20 years of experience in institutional asset management, wealth management, and capital markets. Cohen founded and served as principal of the Iroquois Capital Opportunity Fund, a closed-end private equity fund which focused on investments in North American oil and gas. Cohen also co-founded Iroquois Capital, a New York-based hedge fund that managed approximately $300 million across its family of funds. Prior to Iroquois Capital, Cohen founded a merchant bank which actively participated in structured investments in public companies. Cohen is currently active on a number of public and private company boards and is involved with various charitable ventures.

David Norris, Chief Executive Officer
David Norris is an experienced executive who joined Wrap Technologies full-time in January 2018. From April 2014 to December 2017, he served in various executive roles, including president, at privately held loanDepot LLC as it rapidly expanded into the fifth largest mortgage lender in the U.S. loanDepot had 6,000 employees and generated $1 billion in revenue in 2017. Norris also served as CEO of Greenlight Financial, and president of LendingTree Loans. Norris’ career also includes executive and management roles at Toshiba America Information Systems and Qualcomm Personal. Earlier in his career, Norris served as a probation officer in San Diego for five years.

Tom Smith, President
Tom Smith co-founded TASER International (now Axon Enterprise Inc. (NASDAQ: AAXN)) (“TASER”) in 1993 and served as president of TASER until October 2006. He served as chairman of the board of directors of TASER from October 2006 until he retired to pursue entrepreneurial activities in February 2012. Amongst his most significant roles and responsibilities at TASER, Smith managed domestic and international sales, significantly expanding the sale and distribution of TASER’s products, including sales to more than 17,200 federal, state and local law enforcement agencies in over 100 countries. In 2012, he founded Achilles Technology Solutions LLC, which​, ​through subsidiary ATS Armor, developed a line of ballistic solutions for law enforcement and military applications. Smith holds a B.S. in ecology and evolutionary biology from the University of Arizona and an M.B.A. from Northern Arizona University.

Jim Barnes, Chief Financial Officer
Jim Barnes has served as president of Sunrise Capital Inc., a private venture capital and financial and regulatory consulting firm, since 1984. Barnes was chief financial officer of Parametric Sound Corporation (now Turtle Beach Corporation) and also served as vice president administration at Turtle Beach Corporation. Since 1999, Barnes has been manager of Syzygy Licensing LLC, a private technology invention and licensing company he owns with Elwood Norris. Barnes previously practiced as a certified public accountant and management consultant with Ernst & Ernst and Touche Ross & Co., and as a principal in J. McDonald & Co. Ltd. in Phoenix, Arizona.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• ExploreTech is an exploration technology company that originated at Stanford University, developing an approach to exploration planning that’s more efficient than traditional methods.
• ExploreTech’s probabilistic modeling and drill planning solution pinpoints targets below cover, achieving the same or better drilling results with fewer boreholes.
• Recently, Canamera Energy Metals has engaged ExploreTech to deploy this technology at the Schryburt Lake REE-Niobium Project in Ontario, Canada.

As the world becomes more reliant on technology and makes the shift to clean-energy, the critical metals they rely on are becoming more and more sought after. This increased demand requires a more efficient and effective approach to discover and delineate minerals.

ExploreTech, a Stanford-originated exploration technology company, has developed amore efficient approach to exploration planning than what’s currently available, and demonstrated this technology on over 15 partner projects. The company has shown excellent results, intersecting its predicted targets at every project drilled so far. 

In preparation for its drilling campaign, Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF), a rare earth and critical metals exploration company, has engaged ExploreTech to conduct an independent data review and drill optimization at the Schryburt Lake REE-Niobium Project in Ontario, Canada.

ExploreTech will deploy the company’s proprietary ExploreTech Engine, which is a computing platform that runs probabilistic modeling workflows, to optimize capital spend and refine the depth extent and geometry of the four flagship priority target areas at the Project, which are Goldfinch, Blue Jay, Blackbird, and Starling. 

It’ll also optimize drill collar placement and deliver a ranked, phased drilling sequence in support of Canamera’s recommended 1,500 meter, nine-hole helicopter-supported diamond drilling program.

Speaking about the engagement, Brad Brodeur, CEO of Canamera Energy Metals, said that “Engaging ExploreTech brings a quantitative, evidence-weighted layer to our drill targeting that complements the technical work already completed by the Independent Qualified Person and the Project’s prior operators. ExploreTech’s track record speaks for itself, and partnering with them is consistent with our broader commitment to deploying best-in-class tools across the portfolio to maximize the return on every metre of drilling.”

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

• TechForce Robotics has partnered with NUWA Robotics and Foxconn to support the transition from pilot deployments to scalable commercial production and enterprise rollout
• The company combines AI-driven robotics, enterprise automation infrastructure, and Robotics-as-a-Service capabilities to address growing demand for fleet-scale automation solutions
• Recent expansion into pharmaceutical automation broadens TechForce’s addressable market while reinforcing its strategy of building a scalable robotics commercialization ecosystem

TechForce Robotics, Inc. (“TechForce”), a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), is extending the boundaries of service robotics commercialization, moving its AI-powered automation platforms from pilot deployments into industrial-scale, revenue-generating fleet systems. Reputed for developing autonomous service robots created for logistics, hospitality, healthcare, and commercial settings, the company is now advancing toward full-scale commercialization through integrated manufacturing and deployment partnerships, opening the door to a new era of scalable Robotics-as-a-Service Provider (“RaaSP”) adoption across enterprise markets (ibn.fm/KnktY).

A key milestone in that transition came through a recently announced strategic supply agreement with NUWA Robotics and Foxconn (Hon Hai Precision Industry Co., Ltd.), one of the world’s largest electronics manufacturers. The agreement marks an important evolution from development-stage robotics into commercial production and deployment (ibn.fm/rXOWN). According to the company, the collaboration establishes “a comprehensive framework for the development, manufacturing, and commercialization of next-generation robotic systems” and is intended to position TechForce to scale production efficiently through a globally recognized manufacturing ecosystem.

The structure reflects a deliberate commercialization strategy that separates commercial vision, engineering execution, and manufacturing scale. Under the agreement, TechForce defines product strategy, market requirements, and customer deployment objectives while retaining ownership of its intellectual property. NUWA Robotics contributes engineering development and systems integration expertise, while Foxconn provides manufacturing, testing, assembly, and global fulfillment capabilities. Together, the framework is designed to address one of the most significant challenges facing the robotics industry, converting successful pilot deployments into enterprise-scale rollouts.

TechForce Robotics operates at the intersection of AI-driven automation, deployment infrastructure, service robotics engineering, and emerging pharmaceutical applications. The company is building an ecosystem designed to reduce friction in enterprise adoption by delivering autonomous systems that can be deployed, managed, and scaled across commercial environments. Its platform supports operational functions such as material transport, internal logistics, and service automation within high-traffic facilities.

Beyond manufacturing scale, the company has continued expanding its deployment infrastructure through strategic partnerships aimed at accelerating real-world adoption (ibn.fm/YAEU9). As highlighted in its recent announcement TechForce’s commercial pipeline collaborations intended to support Robotics-as-a-Service growth across hospitality, logistics and healthcare.

The company’s commercialization strategy is also expanding into pharmaceutical and life sciences applications. Through a recently announced initiative focused on pharmaceutical automation, TechForce is applying its robotics expertise to regulated drug development and manufacturing environments, where automation can improve operational efficiency, consistency, and compliance. The move demonstrates the flexibility of the company’s platform architecture and highlights management’s intent to pursue opportunities beyond traditional service robotics markets.

Taken together, these developments illustrate a broader strategy of blending deployment infrastructure with scalable manufacturing capacity, addressing both ends of the commercialization pipeline. As enterprise customers seek fully supported automation solutions rather than isolated pilot programs, companies capable of delivering production-ready systems at scale may be positioned to capture a larger share of growth.

TechForce’s approach is built upon years of real-world deployments across hospitality and service environments, where its systems have been tested, refined, and optimized under operational conditions. The company’s platform combines proprietary autonomous navigation technology, AI-powered fleet management software, and modular robotic systems designed for complex environments

Core systems include Its modular autonomous robot, TIM-E (“Timmy”), which transports items across large, complex facilities using interchangeable attachments to handle logistics such as inventory delivery, linen movement and waste collection, allowing operations to scale without replacing core systems. Alongside this, BIM-E (Beverages in Motion – Everywhere) automates beverage dispensing in high-traffic environments, ensuring consistent pours, reducing waste and maintaining speed during peak demand. 

For investors, the significance of these developments extends beyond the underlying technology. The combination of Foxconn’s manufacturing scale, NUWA’s engineering expertise, expanding deployment partnerships, and entry into pharmaceutical automation suggests that TechForce may be entering a phase where commercialization execution becomes increasingly important to the investment story. Rather than simply developing robotic systems, the company is assembling the infrastructure required to support larger-scale deployments across multiple industries.

For more information, visit the company’s website at TechForceRobotics.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF

• Earth Science Tech Inc. (OTC: ETST) recently reported year-end financial results for the fiscal year ending March 31, 2026
• Earth Science Tech acquires, manages, and operates companies in pharmaceuticals, real estate, telemedicine, healthcare services, and other industries.
• Results include increases in revenue, gross profit, net income, and total assets.

Earth Science Tech (OTC: ETST), a strategic holding company that acquires and manages a diverse portfolio of businesses, recently announced the financial results for the full fiscal year that ended on March 31, 2026 (https://ibn.fm/xRoIz).

The reported results include:

• An 8% revenue increase compared to the year ended March 31, 2025, with revenue rising to $35.7 million from $33.1 million.
• A 5% rise in gross profit, as it climbed to $25.5 million from $24.3 million.
• An 11% increase in net income, as it rose to $3.6 million from $3.3 million.
• Total assets that rose by 27%, going to $9 million from $7.1 million.

Earth Science Tech CEO, Giorgio R. Saumat, said that “Our fiscal 2026 results reflect the meaningful progress we have made over the last several years to build a business that is durable, self-sustaining and positioned for long-term growth.” He added that “These results are driven by the work we have done to better integrate the patient experience across our platform, from telemedicine to pharmacy to fulfillment. By owning more of that process, we serve patients effectively while building a stronger and more profitable business.”

Earth Science Tech builds value by acquiring and managing companies and operates a diverse portfolio of revenue-generating businesses. The company’s core exposure is in acquiring and scaling cash-flowing assets across healthcare, pharmaceutical compounding, and telemedicine. The goal is controlling interests in subsidiaries where operational oversight, regulatory compliance, and disciplined scaling, can drive durable growth, with an emphasis on capital discipline, execution, and long-term value creation.

Earth Science Tech currently has a large portfolio which includes compound pharmacies RxCompoundStore and Mister Meds, telehealth companies MyOnlineConsultation and DOConsultations, as well as Las Villas Health Care, which is both an online telehealth platform and brick-and-mortar clinic. It also operates real estate development firm Avenvi, plus Magnechef, a direct-to-consumer retail brand.

The team at Earth Science Tech is led by CEO and Chairman of the Board, Giorgio R. Saumat. Saumat is an investor and entrepreneur with more than 20 years of experience in investing, operating, and consulting for private businesses and investors. It also features a number of other seasoned professionals with a wealth of experience in areas like finance, technology, business development, and strategic development.

For more information, visit the Earth Science Tech website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• Zacks Investment Research noted progress in the company’s gamification business and potential growth catalysts despite broader industry challenges.
• A key factor was the company’s unique technology, plus improved first-quarter 2026 financial results, including significantly reduced operating losses and positive operating cash flow.
• Versus Systems offers a unique technology platform combining interactive gaming, real-world rewards, and advertising experiences designed to increase customer engagement and loyalty.
• Versus’ Winfinite and Filter Fan Cam products provide opportunities across digital marketing, sports, entertainment, and live-event environments.
• The company’s relationship with ASPIS and the potential extension of its technology licensing agreement may provide future recurring revenue opportunities.

Versus Systems (NASDAQ: VS), a leading provider of gamification and audience engagement technology, has received new attention from the investment community following the initiation of research coverage by Zacks Investment Research, which highlighted the company’s recent operational progress and future growth opportunities (https://ibn.fm/POyah).

The research assessment comes as Versus continues to refine its business model and expand its audience engagement technology during a period when companies across marketing, sports, and media industries are seeking more interactive methods of reaching consumers.

Zacks highlighted how Versus has made notable progress in strengthening its financial position. The company’s first-quarter 2026 results showed a significant reduction in operating losses, driven primarily by lower selling, general, and administrative expenses as well as continued cost management initiatives.

The quarter also marked a meaningful operational milestone as the company generated positive operating cash flow, reflecting improved working-capital management and stronger cash collections. The financial improvements may reduce dependence on external financing while supporting continued investment in technology development.

Zacks also identified several factors that may contribute to future growth. These include the company’s ongoing discussions regarding a potential extension of its technology licensing relationship with ASPIS, which could provide additional recurring revenue and improve visibility into future cash flows.

At the core of Versus’ business is a patented business-to-business engagement platform designed to transform passive audiences into active participants through interactive games, competitions, and real-world rewards. 

The company operates through two primary platforms: Winfinite and Filter Fan Cam (“FFC”). Both products address a common challenge facing marketers and content creators, maintaining consumer attention in an increasingly crowded digital environment.

Winfinite allows brands, agencies, and media companies to create customized interactive campaigns without the time and expense typically associated with building proprietary gaming experiences. The platform includes a collection of adaptable games, including trivia, sports-themed challenges, arcade-style activities, and promotional contests.

Participants can receive a range of rewards depending on the campaign, including discounts, digital incentives, merchandise, and other prizes. By connecting participation with tangible rewards, Versus seeks to create stronger engagement between brands and their audiences. The company’s technology has already reached a substantial user base. According to company materials, more than 10 million consumers have participated in campaigns utilizing Versus technology across sports, entertainment, and corporate environments. 

A key advantage of the platform is its ability to operate across multiple digital and physical channels. Campaigns can be deployed through websites, mobile applications, streaming platforms, broadcasts, and live events, allowing organizations to create consistent engagement strategies across customer touchpoints.

Versus has also expanded its presence in live entertainment through Filter Fan Cam, an augmented reality-based fan engagement solution. The technology incorporates facial tracking and digital effects to create interactive experiences that can appear on venue displays and broadcast feeds. The platform has been used at professional sporting events, including activations involving Major League Baseball’s Texas Rangers at Globe Life Field. For sports teams and venue operators, these experiences can create additional sponsorship opportunities while encouraging deeper fan participation.

The company’s ability to manage reward-based campaigns internationally represents another component of its technology offering. According to corporate information, Versus has distributed rewards across multiple countries, including the United States, United Kingdom, India, China, and Mexico.

This capability is particularly relevant as brands increasingly pursue global digital campaigns that require compliance with different promotional and contest regulations. By providing infrastructure for rewards administration, Versus enables organizations to focus on campaign design and customer interaction.

Versus Systems continues to develop additional products and features intended to broaden its ecosystem. Initiatives such as Play Winfinite aim to expand social and competitive gaming experiences by allowing users to participate with friends and communities while earning rewards.

For more information, visit the company’s website at www.VersusSystems.com.

NOTE TO INVESTORS: The latest news and updates relating to VS are available in the company’s newsroom at https://ibn.fm/VSI

• VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing.
• The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
• VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
• The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”),  and other antibody-based formats.
• VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://ibn.fm/ZcS3w).

The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results provide initial evidence supporting the company’s approach of using dual-targeted mechanisms to activate potent therapeutic payloads only when both components reach the same tumor cell.

Traditional antibody-drug conjugates have transformed parts of cancer treatment by allowing targeted delivery of highly potent therapies. However, a continuing challenge within the field is the unintended exposure of healthy tissue to toxic payloads, which can limit dosing and contribute to adverse effects.

VERAXA’s BiTAC strategy, short for Bi-targeted Tumor-Associated Cytotoxicity, seeks to address this challenge by separating a therapeutic system into two complementary molecules. Individually, these molecules are designed to remain inactive. Therapeutic activity occurs only when both components bind to the intended cancer cell, creating an “AND-gated” approach aimed at improving tumor specificity.

According to the company, this architecture is being applied across two major technology platforms: BiTAC-ADCs and BiTAC-TCEs. The BiTAC-TCE platform was previously presented at the American Association for Cancer Research (“AACR”) Annual Meeting in 2026, where early preclinical data showed selective activity against cells expressing both target markers while reducing effects on cells carrying only one of the targets. Together, the BiTAC-ADC and BiTAC-TCE programs represent VERAXA’s strategy of developing conditionally activated therapies that may offer a broader therapeutic window compared with conventional approaches.

The company entered the public markets in June 2026 following the completion of its business combination with Voyager Acquisition Corp., beginning trading on the NASDAQ Capital Market under the ticker symbol VRXA. The listing provides VERAXA with greater access to capital markets as it advances its pipeline and evaluates future collaboration opportunities.

Beyond its BiTAC programs, VERAXA is developing a broader portfolio of antibody-based therapeutics focused on oncology. The company’s pipeline includes additional mono- and bispecific ADC programs, and other engineered therapeutic formats.

Its most advanced clinical-stage program, VX-A901, is a monoclonal antibody targeting FLT3 for the treatment of acute myeloid leukemia (“AML”). The therapy is designed to stimulate antibody-dependent cellular cytotoxicity, helping immune cells recognize and attack cancer cells. Early Phase I data indicated that the treatment was well tolerated among heavily pre-treated AML patients and showed initial signs of anti-tumor activity. As VERAXA increases its emphasis on solid tumor applications and BiTAC-based modalities, it intends to seek partners for the future development and commercialization of VX-A901.

The company’s research strategy reflects broader trends within the oncology industry, where pharmaceutical developers are increasingly investing in therapies that can improve targeting precision and reduce damage to healthy tissue. ADCs and bispecific antibodies have become important areas of research because they combine the specificity of antibodies with powerful therapeutics. 

Market forecasts indicate substantial growth opportunities in these sectors. According to Grand View Research, the global antibody-drug conjugates market was valued at approximately $12.26 billion in 2024 and is expected to reach about $32.11 billion by 2033, driven by increasing demand for targeted cancer treatments (https://ibn.fm/9L2vF). The market for bispecific antibodies is also projected to expand significantly over the next decade, supported by continued advances in immuno-oncology and precision medicine.

VERAXA traces its scientific origins to discoveries made at the European Molecular Biology Laboratory (“EMBL”), a research institution recognized for contributions to molecular biology and biotechnology. The company has built its development platform around proprietary antibody engineering technologies, biorthogonal click chemistry, and tumor-selective activation strategies designed to create more precise cancer therapeutics.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA